SAT sets aside SEBI order in Morpen Laboratories case

The Securities Appellate Tribunal (SAT) has set aside the order of regulator SEBI, which banned Morpen Laboratories from the capital market for a year. In September 2019, SEBI banned Morpen Laboratories for a year from the Capital Market for making misleading revelations about the issuance of Global Depository Receipts (GDRs) in 2003.For this, the company …

SAT sets aside SEBI order in Morpen Laboratories case Read More »